Unbinding Pathways of GW4064 from Human Farnesoid X Receptor As Revealed by Molecular Dynamics Simulations

Farnesoid X receptor (FXR, NR1H4) is a member of a nuclear receptor superfamily, which plays important roles in bile acid homeostasis, lipoprotein and glucose metabolism, and hepatic regeneration. GW4064 is a potent and selective FXR agonist and has become a tool compound to probe the physiological functions of FXR. Until now, the mechanism of GW4064 entering and leaving the FXR pocket is still poorly understood. Here, we report a computational study of GW4064 unbinding pathways from FXR by using several molecular dynamics (MD) simulation techniques. Based on the crystal structure of FXR in complex with GW4064, conventional MD was first used to refine the binding and check the stability of GW4064 in the FXR pocket. Random acceleration MD simulations were then performed to explore the possible unbinding pathways of GW4064 from FXR. Four main pathway clusters were found, among which three subpathways, namely Paths 2A, 2B, and 1B, were observed most frequently. Multiple steered MD simulations were further employed to estimate the maximum rupture force and the sum of the forces and to characterize the intermediate states of the ligand unbinding process. By comparing the average force profiles and structural changes, Paths 2A and 2B were identified to be the most favorable unbinding pathways. The former is located between the H1-H2 loop and the H5-H6 loop, and the latter is located in the cleft formed by the H5-H6 loop, H6, and H7. Moreover, the residues lining the pathways were analyzed for their roles in ligand unbinding. Based on our results, the possible structural modification strategies on GW4064 were also proposed.

[1]  Stefan Westin,et al.  Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). , 2009, Journal of medicinal chemistry.

[2]  A. Cavalli,et al.  Single-molecule pulling simulations can discern active from inactive enzyme inhibitors. , 2010, Journal of the American Chemical Society.

[3]  Shawn P Williams,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. , 2008, Bioorganic & medicinal chemistry letters.

[4]  P. Tavan,et al.  Ligand Binding: Molecular Mechanics Calculation of the Streptavidin-Biotin Rupture Force , 1996, Science.

[5]  Peter D Siersema,et al.  Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine. , 2011, Biochimica et biophysica acta.

[6]  Vikas Chandra,et al.  Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. , 2010, Annual review of physiology.

[7]  M Karplus,et al.  Retinoic acid receptor: a simulation analysis of retinoic acid binding and the resulting conformational changes. , 1999, Journal of molecular biology.

[8]  Yan Zhang,et al.  FXR ligands protect against hepatocellular inflammation via SOCS3 induction. , 2012, Cellular signalling.

[9]  William L. Jorgensen,et al.  Drug discovery: Pulled from a protein's embrace , 2010, Nature.

[10]  Weihua Li,et al.  Exploring coumarin egress channels in human cytochrome p450 2a6 by random acceleration and steered molecular dynamics simulations , 2011, Proteins.

[11]  Manfred Schubert-Zsilavecz,et al.  Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. , 2012, Future medicinal chemistry.

[12]  Olivier Michielin,et al.  Protein-protein interaction investigated by steered molecular dynamics: the TCR-pMHC complex. , 2008, Biophysical journal.

[13]  B. Kuhn,et al.  Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. , 2011, Bioorganic & medicinal chemistry letters.

[14]  M. L. Crawley,et al.  Farnesoid X receptor modulators: a patent review , 2010, Expert Opinion on Therapeutic Patents.

[15]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[16]  Roberto Pellicciari,et al.  Structural basis for bile acid binding and activation of the nuclear receptor FXR. , 2003, Molecular cell.

[17]  N. Garnier,et al.  Ligand-escape pathways from the ligand-binding domain of PPARγ receptor as probed by molecular dynamics simulations , 2008, European Biophysics Journal.

[18]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[19]  Shawn P Williams,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. , 2011, Bioorganic & medicinal chemistry letters.

[20]  K. Schulten,et al.  Unbinding of retinoic acid from its receptor studied by steered molecular dynamics. , 1999, Biophysical journal.

[21]  A. Zampella,et al.  Farnesoid X receptor: from medicinal chemistry to clinical applications. , 2012, Future medicinal chemistry.

[22]  R. Wade,et al.  How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanisms. , 2000, Journal of molecular biology.

[23]  Weihua Li,et al.  Reduced Catalytic Activity of P450 2A6 Mutants with Coumarin: A Computational Investigation. , 2009, Journal of chemical theory and computation.

[24]  K. Schulten,et al.  Steered molecular dynamics and mechanical functions of proteins. , 2001, Current opinion in structural biology.

[25]  Wendong Huang,et al.  FXR, a target for different diseases. , 2008, Histology and histopathology.

[26]  Yi-Ping Phoebe Chen,et al.  Exploring Inhibitor Release Pathways in Histone Deacetylases Using Random Acceleration Molecular Dynamics Simulations , 2012, J. Chem. Inf. Model..

[27]  Helmut Grubmüller,et al.  Ligand-release pathways in the pheromone-binding protein of Bombyx mori. , 2006, Structure.

[28]  M. Peräkylä.  Ligand unbinding pathways from the vitamin D receptor studied by molecular dynamics simulations , 2009, European Biophysics Journal.

[29]  Feixiong Cheng,et al.  Investigation of Indazole Unbinding Pathways in CYP2E1 by Molecular Dynamics Simulations , 2012, PloS one.

[30]  Yong Duan,et al.  Chromophore channeling in the G-protein coupled receptor rhodopsin. , 2007, Journal of the American Chemical Society.

[31]  Yanqiao Zhang,et al.  Activation of the Farnesoid X Receptor Induces Hepatic Expression and Secretion of Fibroblast Growth Factor 21* , 2012, The Journal of Biological Chemistry.

[32]  B. Staels,et al.  FXR: a promising target for the metabolic syndrome? , 2007, Trends in pharmacological sciences.

[33]  Lennart Nilsson,et al.  Unbinding of retinoic acid from the retinoic acid receptor by random expulsion molecular dynamics. , 2006, Biophysical journal.

[34]  Shawn P. Williams,et al.  FXR agonist activity of conformationally constrained analogs of GW 4064. , 2009, Bioorganic & medicinal chemistry letters.

[35]  Gabriele Costantino,et al.  Farnesoid X receptor: from structure to potential clinical applications. , 2005, Journal of medicinal chemistry.

[36]  K. Sharp,et al.  Calculating the electrostatic potential of molecules in solution: Method and error assessment , 1988 .

[37]  Jan H. Jensen,et al.  Very fast empirical prediction and rationalization of protein pKa values , 2005, Proteins.

[38]  C. Jarzynski.  Nonequilibrium Equality for Free Energy Differences , 1996, cond-mat/9610209.

[39]  Leandro Martínez,et al.  Ligand dissociation from estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations. , 2008, Molecular endocrinology.

[40]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[41]  Rebecca C Wade,et al.  Multiple, ligand-dependent routes from the active site of cytochrome P450 2C9. , 2012, Current drug metabolism.

[42]  Lennart Nilsson,et al.  Ligand unbinding from the estrogen receptor: A computational study of pathways and ligand specificity , 2009, Proteins.

[43]  Yanqiao Zhang,et al.  FXR, a multipurpose nuclear receptor. , 2006, Trends in biochemical sciences.

[44]  Timothy M Willson,et al.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Rebecca C Wade,et al.  Do mammalian cytochrome P450s show multiple ligand access pathways and ligand channelling? , 2005, EMBO reports.

[46]  G. B. Wisely,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene. , 2011, Bioorganic & medicinal chemistry letters.

[47]  Quentin Kaas,et al.  Delineation of the unbinding pathway of α-conotoxin ImI from the α7 nicotinic acetylcholine receptor. , 2012, The journal of physical chemistry. B.

[48]  Leandro Martínez,et al.  Molecular dynamics simulations reveal multiple pathways of ligand dissociation from thyroid hormone receptors. , 2005, Biophysical journal.

[49]  Leandro Martínez,et al.  Molecular dynamics simulations of ligand dissociation from thyroid hormone receptors: evidence of the likeliest escape pathway and its implications for the design of novel ligands. , 2006, Journal of medicinal chemistry.

[50]  Marco Migliorati,et al.  Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. , 2011, Biochimica et biophysica acta.

[51]  Hualiang Jiang,et al.  Computational insights into the mechanism of ligand unbinding and selectivity of estrogen receptors. , 2009, The journal of physical chemistry. B.

[52]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[53]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[54]  Nahum Méndez-Sánchez,et al.  Intestinal nuclear bile acid receptor FXR and cholestasis. , 2012, Annals of hepatology.

[55]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..